about
Melanoma: from melanocyte to genetic alterations and clinical optionsFocus on adoptive T cell transfer trials in melanomaInterferon alpha for the adjuvant treatment of cutaneous melanomaInterferon alpha for the adjuvant treatment of cutaneous melanomaSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenibAnalysis of the genome to personalize therapy for melanomaArginine deprivation therapy for malignant melanomaAdoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimensInvolvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanomaMelanoma immunotherapy dominates the fieldResistant mechanisms to BRAF inhibitors in melanomaNatural Killer Cell Recognition of Melanoma: New Clues for a More Effective ImmunotherapyThe GIST of targeted therapy for malignant melanomaEmergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterialsSystematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanomaThe pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapyActivity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation.Improved Survival with Ipilimumab in Patients with Metastatic MelanomaCutaneous Melanoma in AsiansTrial Watch-Immunostimulation with cytokines in cancer therapyRhoJ regulates melanoma chemoresistance by suppressing pathways that sense DNA damageActivated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma modelHypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cellsNanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A ReviewExosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatinCutaneous side effects of vemurafenib: a case report and discussion.Improvement of overall survival in stage IV melanoma patients during 2011-2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR).SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas.Melanoma screening with cellular phones.Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cellsAn evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo.Overexpression of Chromatin Assembly Factor-1/p60 helps to predict the prognosis of melanoma patients.Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.Cutaneous melanoma: new advances in treatment.Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivoTargeted Therapy Database (TTD): a model to match patient's molecular profile with current knowledge on cancer biology
P2860
Q21284811-C6444670-2F5F-46AD-A4F3-D0C3B50AF4CAQ21328679-BE325DB4-E58E-4A7C-946C-B1D1BC1C2C7FQ24201908-90903222-4523-454E-AA14-BE4A9F1F0610Q24235257-384925CA-B2D6-42BE-8F90-169C6560589CQ24594790-0D9ED4E5-56CF-445D-90C5-BBD5C81342FBQ24601008-5232896E-CE90-4BA2-B7C1-EA5DB6D81BFCQ24634269-231CFA24-632F-4EA1-AD74-35909193BC12Q24644442-32F474B0-6F99-460B-B801-9A0156F2F8A1Q24649754-7B193A7A-C384-4413-945D-BCABAC33360DQ26738671-3F6FE2CB-73E8-4572-8670-BEC8222BF8E5Q26739717-18178268-0555-4E08-93CE-EEBAB166E1DBQ26771449-E0EC0FB2-21D3-4286-BFAF-C1292872CCF4Q26827092-81D5534D-5189-4415-BCF2-5DEA2961C0ADQ26860518-E73C50C1-3DF6-48B4-AF06-49A651F96C9DQ26996629-F0304325-989D-484C-8E1E-B232793705CCQ27004672-32986FE9-75DC-4BBA-B6F1-F34B75867F45Q27851482-66E1970D-4126-49BD-ADE3-9F41F18EB5CEQ27851483-14E3B1AD-13D6-4013-9D3E-6E221E7BA842Q27851856-13107800-5D20-4150-89FC-5DB9B43A6376Q27852894-3CD70DD8-7EFA-4501-95CB-9DFAD2A51CB2Q27853361-E10E4EE1-8707-45D6-A5C5-2C7839F1A0ECQ27861062-1C1F7FAA-F64E-495B-9D40-D160F525DC24Q28078576-7981E306-6563-40CC-85C6-C8C8CE69BA15Q28078725-F17A7A33-C5EA-42DF-9597-CA0670884C30Q28274939-4C418860-A681-4F51-825D-1C0302193453Q28306770-5FC37738-0821-4C89-8AEB-34B6625CB2EBQ28393898-719EA993-2827-4E14-AC2E-A26FB2FF53DCQ28394719-2250F687-A2E6-4708-A18A-8690BCF9C054Q28539631-5E0CC1CD-9E08-482E-9881-8965A44294D1Q30456779-66A4955C-5F56-4617-A557-65F9BF33695BQ31144246-1D5B83FE-9FF4-4FA0-AF6E-92D0E1531759Q33273549-A844DDE2-8C7D-49B3-B3C7-74B657C7DD77Q33286033-FADE4B9B-F0A2-4F76-B611-264957CB0405Q33445569-BEA6A668-3C7A-4530-A9D6-BFE471220493Q33529309-B552B51A-A10C-4835-98D3-03AEA230632CQ33533679-AECBFFF1-B971-4DE8-8ACE-D2FD400E8A45Q33557480-C1EB1273-CA17-42BA-9721-D376AFADF7A5Q33558587-9054DCD2-8F8E-4D2A-ACBD-E657ED77AA1AQ33638956-992C8989-DB2B-4F56-96A3-81408C3E5A57Q33656600-DCEF6589-5FAC-41D9-BD97-1681A45F13A2
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Management of cutaneous melanoma.
@ast
Management of cutaneous melanoma.
@en
type
label
Management of cutaneous melanoma.
@ast
Management of cutaneous melanoma.
@en
prefLabel
Management of cutaneous melanoma.
@ast
Management of cutaneous melanoma.
@en
P2093
P356
P1476
Management of cutaneous melanoma.
@en
P2093
Arthur J Sober
Hensin Tsao
Michael B Atkins
P304
P356
10.1056/NEJMRA041245
P407
P577
2004-09-01T00:00:00Z